Medicated Skin Care in France

Summary

Euromonitor International's Medicated Skin Care in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, distribution or pricing issues. Forecasts to 2013 illustrate how the market is set to change.

Product coverage: acne treatments, antipruritics, topical germicidals/antiseptics, topical allergy remedies/antihistamines, topical antifungals, vaginal antifungals, antiparasitics/lice (head and body) treatments, medicated shampoos, hair loss treatments, lip care treatments, haemorrhoid treatments, child-specific medicated skin care, nappy (diaper) rash treatments

Data coverage: market sizes (historic and forecasts), company shares and brand shares

Why buy this report?

• Get a detailed picture of the medicated skin care industry
• Identify factors driving change
• Understand the competitive environment, the market's major players and leading brands
• Use five-year forecasts to assess how the market is predicted to develop

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor has a unique capability to develop reliable information resources to help drive informed strategic planning

Contents

• Medicated Skin Care in France
• Euromonitor International
• April 2009
• Executive Summary
• OTC Healthcare Suffers From Consumers Obtaining More Prescription Products
• Increasing Presence of Self-service Areas in Chemists/pharmacies for OTC Products
• A Fragmented Market Led by OTC Manufacturers
• Chemists/pharmacies Remains the Leading Distribution Channel
• Positive Performance Through the Development of Self-medication
• Key Trends and Developments
• the Setting-up of Self-service: Its Impact on Self-medication
• Vitamins and Dietary Supplements for Everyone
• the Grey Market Is the New Key Target Consumer Group
• Decreasing Purchasing Power Favours Rx Products
• Market Indicators
• Market Data
• $1OTC Registration and Classification
• Advertising
• Packaging and Labelling
• Distribution
• Vitamins & Dietary Supplements Registration and Classification
• EU Legislation
• Self-medication and Preventative Medicine
• Generics
• Switches
• Definitions
• Arkopharma Sa, Laboratoires Pharmaceutiques
• Strategic Direction
• Key Facts
• Company Background
• Competitive Positioning
• Beaufour-ipsen SA
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• Cooper SA
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• GlaxoSmithKline Sant Grand Public Sas
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• Juva Sant, Laboratoires
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• Laboratoires Mcneil
• Strategic Direction
• Key Facts
• Company Background
• Competitive Positioning
• Pierre Fabre Sa, Laboratoires
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• Thraplix SA
• Strategic Direction
• Key Facts
• Company Background
• Competitive Positioning
• Upsa, Laboratoires
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• Urgo, Laboratoires
• Strategic Direction
• Key Facts
• Company Background
• Production
• Competitive Positioning
• Headlines
• Trends
• Competitive Landscape
• Prospects
• Sector Data
• List of Summaries
  • Summary 1 Rx-to-OTC Healthcare Switches 2006-2008
  • Summary 2 Research Sources
  • Summary 3 Laboratoires Pharmaceutiques Arkopharma SA: Key Facts
  • Summary 4 Laboratoires Pharmaceutiques Arkopharma SA: Operational Indicators
  • Summary 5 Laboratoires Pharmaceutiques Arkopharma SA: Competitive Position 2008
  • Summary 6 Beaufour-Ipsen SA: Key Facts
  • Summary 7 Beaufour-Ipsen SA: Operational Indicators
  • Summary 8 Beaufour-Ipsen SA: Production Statistics 2007
  • Summary 9 Beaufour-Ipsen SA: Competitive Position 2008
  • Summary 10 Cooper SA: Key Facts
  • Summary 11 Cooper SA: Operational Indicators
  • Summary 12 Cooper SA: Production Statistics 2007
  • Summary 13 Cooper SA: Competitive Position 2008
  • Summary 14 GlaxoSmithKline Sant Grand Public SAS: Key Facts
  • Summary 15 GlaxoSmithKline Sant Grand Public SAS: Operational Indicators
  • Summary 16 GlaxoSmithKline France: Production Statistics 2007
  • Summary 17 GlaxoSmithKline Sant Grand Public SAS: Competitive Position 2008
  • Summary 18 Laboratoires Juva Sant: Key Facts
  • Summary 19 Laboratoires Juva Sant: Operational Indicators
  • Summary 20 Laboratoires Juva Sant: Production Statistics 2006
  • Summary 21 Laboratoires Juva Sant: Competitive Position 2008
  • Summary 22 Laboratoires McNeil: Key Facts
  • Summary 23 Laboratoires McNeil: Operational Indicators
  • Summary 24 Laboratoires McNeil: Competitive Position 2008
  • Summary 25 Laboratoires Pierre Fabre SA: Key Facts
  • Summary 26 Laboratoires Pierre Fabre SA: Operational Indicators
  • Summary 27 Laboratoires Pierre Fabre SA: Production Statistics 2007
  • Summary 28 Laboratoires Pierre Fabre SA: Competitive Position 2008
  • Summary 29 Thraplix SA: Key Facts
  • Summary 30 Thraplix SA: Competitive Position 2008
  • Summary 31 Laboratoires UPSA: Key Facts
  • Summary 32 Laboratoires UPSA: Operational Indicators
  • Summary 33 UPSA Conseil SAS: Production Statistics 2007
  • Summary 34 UPSA Conseil SAS: Competitive Position 2008
  • Summary 35 Laboratoires Urgo: Key Facts
  • Summary 36 Laboratoires Urgo: Operational Indicators
  • Summary 37 Laboratoires Urgo: Competitive Position 2008
• List of Tables
  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2003-2008
  • Table 2 Life Expectancy at Birth 2003-2008
  • Table 3 Sales of OTC Healthcare by Sector: Value 2003-2008
  • Table 4 Sales of OTC Healthcare by Sector: % Value Growth 2003-2008
  • Table 5 OTC Healthcare Company Shares by Value 2004-2008
  • Table 6 OTC Healthcare Brand Shares by Value 2005-2008
  • Table 7 Penetration of Private Label by Sector 2003-2008
  • Table 8 Sales of OTC Healthcare by Distribution Format: % Analysis 2003-2008
  • Table 9 Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2008
  • Table 10 Forecast Sales of OTC Healthcare by Sector: Value 2008-2013
  • Table 11 Forecast Sales of OTC Healthcare by Sector: % Value Growth 2008-2013
  • Table 12 Sales of Medicated Skin Care by Subsector: Value 2003-2008
  • Table 13 Sales of Medicated Skin Care by Subsector: % Value Growth 2003-2008
  • Table 14 Herbal vs Standard Medicated Skin Care 2003-2008
  • Table 15 Acne Treatments by Format: % Value Breakdown 2004-2008
  • Table 16 Medicated Skin Care Company Shares by Value 2004-2008
  • Table 17 Medicated Skin Care Brand Shares by Value 2005-2008
  • Table 18 Acne Treatments Brand Shares by Value 2005-2008
  • Table 19 Hair Loss Treatments Brand Shares by Value 2005-2008
  • Table 20 Forecast Sales of Medicated Skin Care by Subsector: Value 2008-2013
  • Table 21 Forecast Sales of Medicated Skin Care by Subsector: % Value Growth 2008-2013